Aprea Therapeutics, Inc. (APRE )

Currency in USD Disclaimer
$3.05 +$0.49 (19.14%)
Closed 10/15/2024
$2.58
$3.2
$2.15
$8.85

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol APRE
  • Company Aprea Therapeutics, Inc.
  • Price $3.05
  • Changes Percentage 19.14
  • Change 0.49
  • Day Low $2.58
  • Day High $3.2
  • Year High $8.85
  • Year Low $2.15
  • Market Cap $16,567,295
  • Price Avg 50 EMA (D) $3.16
  • Price Avg 200 EMA (D) $4.82
  • Exchange NASDAQ
  • Volume 53,940
  • Average Volume 14,226
  • Open $2.6
  • Previous Close $2.56
  • EPS -3.01
  • PE -1.01
  • Earnings Announcement 2024-11-07 10:59:00
  • Shares Outstanding $5,431,900

Company brief: APREA THERAPEUTICS, INC. (APRE )

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

APRE Corporation News

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

October 14, 2024 at 8:30 am ET

globenewswire.com -- DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncolog...

Income Statement